ALVOAlvotech
The schedule
- Tue20Oct
A forced liquidity event or debt restructuring announcement as ALVO navigates its heavily levered balance sheet ahead of 2027 maturities.
- Thu19Nov
Q3 results will provide pivotal insight into FY26 revenue trajectory and whether margins can scale fast enough to service ALVO's debt burden.
- Tue15Dec
Management's strategic outlook for 2027, including preliminary FY26 revenue figures and timelines for next-generation biosimilar assets.
- Tue9Feb
Full-year 2026 results and the introduction of FY27 financial guidance, a critical test for ALVO's long-term commercial viability.
- Wed10Mar
- Mon10May
Past
- Wed30Sep
Late Q3 updates on international biosimilar approvals and U.S. launch execution metrics, critical for ALVO's top-line inflection.
- Wed20May
Actual outcome: Bull · $3.70 at outcome
ALVO reported EPS actual of 0.0031, matching the estimate, and provided guidance that signaled stabilization in demand. The company also announced a strategic rebrand and key partnerships, which reinforced long-term growth prospects and drove the stock higher despite the neutral earnings report.
